| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Genetic Heterogeneity | 11 | 2019 | 77 | 3.93 | Why? |
| Chromosomal Instability | 6 | 2018 | 9 | 2.43 | Why? |
| Drug Resistance, Neoplasm | 8 | 2019 | 447 | 2.13 | Why? |
| Aneuploidy | 4 | 2018 | 27 | 1.70 | Why? |
| Clonal Evolution | 5 | 2018 | 55 | 1.46 | Why? |
| Neoplasms | 21 | 2021 | 17251 | 1.38 | Why? |
| Biomarkers, Tumor | 7 | 2019 | 1314 | 0.99 | Why? |
| Carcinoma, Renal Cell | 5 | 2018 | 545 | 0.80 | Why? |
| Tumor Microenvironment | 3 | 2018 | 264 | 0.79 | Why? |
| DNA Copy Number Variations | 3 | 2018 | 84 | 0.78 | Why? |
| Biomarkers, Pharmacological | 2 | 2017 | 150 | 0.77 | Why? |
| Carcinoma, Non-Small-Cell Lung | 5 | 2018 | 896 | 0.75 | Why? |
| Circulating Tumor DNA | 1 | 2018 | 46 | 0.74 | Why? |
| Caspase 2 | 1 | 2017 | 1 | 0.70 | Why? |
| Colorectal Neoplasms | 5 | 2021 | 1884 | 0.62 | Why? |
| Mutation | 17 | 2019 | 12376 | 0.60 | Why? |
| Neoplasm Recurrence, Local | 4 | 2018 | 1063 | 0.58 | Why? |
| High-Throughput Nucleotide Sequencing | 7 | 2019 | 3633 | 0.58 | Why? |
| Genome, Human | 2 | 2018 | 400 | 0.57 | Why? |
| Medical Oncology | 2 | 2021 | 3826 | 0.53 | Why? |
| DNA-Binding Proteins | 1 | 2017 | 469 | 0.52 | Why? |
| Lung Neoplasms | 9 | 2019 | 3228 | 0.48 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.48 | Why? |
| Biological Evolution | 1 | 2018 | 641 | 0.46 | Why? |
| Neoplasm Metastasis | 4 | 2018 | 682 | 0.45 | Why? |
| Transcription Factors | 1 | 2017 | 784 | 0.43 | Why? |
| Drug Resistance, Multiple | 1 | 2011 | 156 | 0.40 | Why? |
| Neoplasm Proteins | 1 | 2015 | 501 | 0.40 | Why? |
| Biomedical Research | 2 | 2021 | 5270 | 0.40 | Why? |
| Genomic Instability | 3 | 2018 | 80 | 0.39 | Why? |
| Cysteine Endopeptidases | 1 | 2017 | 1557 | 0.35 | Why? |
| Cell Transformation, Neoplastic | 2 | 2017 | 191 | 0.31 | Why? |
| Kidney Neoplasms | 3 | 2018 | 832 | 0.29 | Why? |
| Molecular Targeted Therapy | 4 | 2018 | 1579 | 0.29 | Why? |
| Tumor Suppressor Protein p53 | 2 | 2018 | 310 | 0.29 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.29 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.28 | Why? |
| Antineoplastic Agents | 2 | 2017 | 3550 | 0.26 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1573 | 0.26 | Why? |
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 1014 | 0.24 | Why? |
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 43 | 0.22 | Why? |
| Gene Amplification | 2 | 2019 | 85 | 0.22 | Why? |
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 130 | 0.22 | Why? |
| Chromosome Segregation | 2 | 2018 | 10 | 0.22 | Why? |
| Mitosis | 2 | 2018 | 43 | 0.22 | Why? |
| United Kingdom | 8 | 2021 | 18046 | 0.21 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.21 | Why? |
| Receptor, ErbB-2 | 2 | 2019 | 267 | 0.21 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.20 | Why? |
| Cell-in-Cell Formation | 1 | 2018 | 1 | 0.19 | Why? |
| Medical Laboratory Science | 1 | 2020 | 122 | 0.19 | Why? |
| Exome | 2 | 2017 | 207 | 0.19 | Why? |
| ErbB Receptors | 2 | 2018 | 320 | 0.18 | Why? |
| Centrosome | 1 | 2017 | 12 | 0.18 | Why? |
| Cytosol | 1 | 2018 | 77 | 0.18 | Why? |
| Trastuzumab | 1 | 2019 | 108 | 0.18 | Why? |
| DNA, Neoplasm | 1 | 2018 | 56 | 0.18 | Why? |
| Humans | 61 | 2021 | 930598 | 0.18 | Why? |
| Neoplasm, Residual | 1 | 2018 | 147 | 0.18 | Why? |
| Cerebellar Neoplasms | 1 | 2017 | 12 | 0.18 | Why? |
| BH3 Interacting Domain Death Agonist Protein | 1 | 2017 | 4 | 0.17 | Why? |
| Prion Proteins | 1 | 2017 | 12 | 0.17 | Why? |
| Ipilimumab | 1 | 2018 | 102 | 0.17 | Why? |
| Medulloblastoma | 1 | 2017 | 15 | 0.17 | Why? |
| 5'-Nucleotidase | 1 | 2017 | 21 | 0.17 | Why? |
| Coculture Techniques | 1 | 2018 | 258 | 0.17 | Why? |
| HCT116 Cells | 1 | 2017 | 83 | 0.17 | Why? |
| Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 35 | 0.17 | Why? |
| Evolution, Molecular | 4 | 2018 | 3691 | 0.16 | Why? |
| Clone Cells | 1 | 2017 | 312 | 0.16 | Why? |
| Epigenomics | 1 | 2017 | 139 | 0.16 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.15 | Why? |
| Genes, Neoplasm | 1 | 2015 | 26 | 0.15 | Why? |
| Whole Exome Sequencing | 1 | 2018 | 437 | 0.15 | Why? |
| Urine | 1 | 2018 | 469 | 0.15 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 347 | 0.15 | Why? |
| Breast Neoplasms | 4 | 2018 | 3633 | 0.15 | Why? |
| Residential Facilities | 1 | 2020 | 443 | 0.15 | Why? |
| Prognosis | 5 | 2018 | 32490 | 0.15 | Why? |
| Mutagenesis | 1 | 2017 | 394 | 0.14 | Why? |
| Genome | 1 | 2017 | 341 | 0.14 | Why? |
| Antineoplastic Agents, Immunological | 2 | 2019 | 830 | 0.14 | Why? |
| Models, Genetic | 1 | 2017 | 434 | 0.14 | Why? |
| Mice | 7 | 2018 | 21357 | 0.14 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.13 | Why? |
| Brain Neoplasms | 2 | 2018 | 669 | 0.13 | Why? |
| B7-H1 Antigen | 1 | 2017 | 541 | 0.13 | Why? |
| Cell Line, Tumor | 4 | 2018 | 3608 | 0.13 | Why? |
| Antigens, Neoplasm | 1 | 2015 | 230 | 0.13 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.12 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2019 | 760 | 0.12 | Why? |
| Stress, Physiological | 1 | 2017 | 378 | 0.12 | Why? |
| Animals | 11 | 2020 | 78931 | 0.12 | Why? |
| Urologic Neoplasms | 1 | 2017 | 348 | 0.12 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.12 | Why? |
| Immunotherapy, Adoptive | 1 | 2017 | 524 | 0.12 | Why? |
| Ploidies | 1 | 2011 | 5 | 0.12 | Why? |
| Urinary Bladder Neoplasms | 1 | 2018 | 614 | 0.11 | Why? |
| Waiting Lists | 1 | 2020 | 1388 | 0.11 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2018 | 5837 | 0.11 | Why? |
| Lymph Nodes | 1 | 2017 | 1060 | 0.10 | Why? |
| Adenocarcinoma | 1 | 2017 | 651 | 0.10 | Why? |
| In Situ Hybridization, Fluorescence | 1 | 2011 | 207 | 0.10 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.10 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.10 | Why? |
| Treatment Failure | 1 | 2015 | 2106 | 0.09 | Why? |
| Long-Term Care | 1 | 2020 | 2047 | 0.09 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.09 | Why? |
| Epilepsy | 1 | 2020 | 1401 | 0.09 | Why? |
| Lymphocyte Activation | 1 | 2018 | 2742 | 0.09 | Why? |
| Aged, 80 and over | 13 | 2020 | 88759 | 0.09 | Why? |
| Cross Infection | 2 | 2020 | 8675 | 0.09 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.08 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.08 | Why? |
| Antibodies, Neutralizing | 4 | 2021 | 25288 | 0.08 | Why? |
| Anthracyclines | 1 | 2006 | 65 | 0.08 | Why? |
| INDEL Mutation | 2 | 2017 | 128 | 0.08 | Why? |
| Immune Evasion | 1 | 2017 | 2081 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2017 | 3607 | 0.08 | Why? |
| Cell Proliferation | 3 | 2018 | 1973 | 0.08 | Why? |
| Antibiotics, Antineoplastic | 1 | 2006 | 128 | 0.08 | Why? |
| Immunologic Memory | 1 | 2018 | 3362 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.08 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.07 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.07 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.07 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.07 | Why? |
| Sequence Analysis, DNA | 3 | 2018 | 2830 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Transcriptome | 1 | 2017 | 3466 | 0.07 | Why? |
| Female | 20 | 2020 | 380317 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.06 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.06 | Why? |
| Aged | 15 | 2020 | 215776 | 0.06 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Male | 19 | 2021 | 367725 | 0.06 | Why? |
| Alleles | 2 | 2018 | 1557 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.06 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.06 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.05 | Why? |
| Healthcare Disparities | 1 | 2018 | 3893 | 0.05 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| Neoplasm Staging | 2 | 2017 | 1999 | 0.05 | Why? |
| Adult | 15 | 2021 | 244371 | 0.05 | Why? |
| Chromosomes, Human, Pair 14 | 1 | 2018 | 4 | 0.05 | Why? |
| Neoplasm Transplantation | 1 | 2018 | 55 | 0.05 | Why? |
| Mesoderm | 1 | 2018 | 15 | 0.05 | Why? |
| Chromosomes | 1 | 2018 | 17 | 0.05 | Why? |
| Micronuclei, Chromosome-Defective | 1 | 2018 | 8 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Oncogenes | 1 | 2017 | 23 | 0.05 | Why? |
| 3T3 Cells | 1 | 2018 | 152 | 0.05 | Why? |
| Heterografts | 1 | 2018 | 203 | 0.04 | Why? |
| Chromosomes, Human, Pair 9 | 1 | 2018 | 196 | 0.04 | Why? |
| Hedgehog Proteins | 1 | 2018 | 39 | 0.04 | Why? |
| Tumor Cells, Cultured | 1 | 2018 | 254 | 0.04 | Why? |
| Chromosome Mapping | 1 | 2018 | 178 | 0.04 | Why? |
| Tumor Burden | 1 | 2019 | 369 | 0.04 | Why? |
| Cyclin-Dependent Kinases | 1 | 2017 | 124 | 0.04 | Why? |
| Europe | 3 | 2020 | 12702 | 0.04 | Why? |
| Nucleotidyltransferases | 1 | 2018 | 77 | 0.04 | Why? |
| beta Catenin | 1 | 2017 | 78 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Artifacts | 1 | 2019 | 250 | 0.04 | Why? |
| Wnt Signaling Pathway | 1 | 2017 | 87 | 0.04 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2018 | 274 | 0.04 | Why? |
| Kidney Tubules, Proximal | 1 | 2018 | 178 | 0.04 | Why? |
| Indazoles | 1 | 2017 | 77 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 9335 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.04 | Why? |
| Academies and Institutes | 1 | 2020 | 539 | 0.04 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 179 | 0.04 | Why? |
| Phenylurea Compounds | 1 | 2017 | 101 | 0.04 | Why? |
| Lymphocyte Count | 2 | 2018 | 4758 | 0.04 | Why? |
| CpG Islands | 1 | 2017 | 230 | 0.04 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.04 | Why? |
| DNA Damage | 1 | 2018 | 285 | 0.04 | Why? |
| Cell Death | 1 | 2018 | 536 | 0.04 | Why? |
| Bevacizumab | 1 | 2017 | 149 | 0.04 | Why? |
| Niacinamide | 1 | 2017 | 135 | 0.04 | Why? |
| Epitope Mapping | 1 | 2020 | 1240 | 0.04 | Why? |
| Disease Models, Animal | 3 | 2018 | 10998 | 0.04 | Why? |
| Lymphatic Metastasis | 1 | 2017 | 537 | 0.04 | Why? |
| Principal Component Analysis | 1 | 2017 | 689 | 0.03 | Why? |
| Promoter Regions, Genetic | 1 | 2018 | 823 | 0.03 | Why? |
| Community-Based Participatory Research | 1 | 2016 | 271 | 0.03 | Why? |
| Phylogeny | 3 | 2018 | 13341 | 0.03 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.03 | Why? |
| Pyrroles | 1 | 2017 | 292 | 0.03 | Why? |
| Organ Specificity | 1 | 2018 | 1070 | 0.03 | Why? |
| London | 1 | 2020 | 2166 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.03 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2017 | 604 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Immunity, Herd | 1 | 2020 | 1011 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| DNA Methylation | 1 | 2017 | 688 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Models, Statistical | 2 | 2020 | 5312 | 0.03 | Why? |
| DNA | 1 | 2017 | 778 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Imidazoles | 1 | 2017 | 631 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| NF-kappa B | 1 | 2018 | 1301 | 0.03 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.03 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| Heart Diseases | 1 | 2006 | 3503 | 0.02 | Why? |
| Respiratory Mucosa | 1 | 2018 | 1522 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Carcinoma, Squamous Cell | 1 | 2018 | 902 | 0.02 | Why? |
| Immunomodulation | 1 | 2018 | 1472 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2020 | 6049 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.02 | Why? |
| Indoles | 1 | 2017 | 1243 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| England | 1 | 2020 | 5116 | 0.02 | Why? |
| Sulfonamides | 1 | 2017 | 1294 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Bayes Theorem | 1 | 2017 | 3237 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2017 | 1585 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.02 | Why? |
| Parents | 1 | 2021 | 2758 | 0.02 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.02 | Why? |
| Killer Cells, Natural | 1 | 2017 | 2093 | 0.02 | Why? |
| HEK293 Cells | 1 | 2020 | 8394 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Amides | 1 | 2018 | 1864 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.02 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Autopsy | 1 | 2016 | 3495 | 0.02 | Why? |
| Head and Neck Neoplasms | 1 | 2018 | 1568 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2018 | 4002 | 0.02 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.02 | Why? |
| Computer Simulation | 1 | 2019 | 4982 | 0.02 | Why? |
| Renal Dialysis | 1 | 2021 | 4358 | 0.02 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Child, Preschool | 2 | 2017 | 36283 | 0.02 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Child | 2 | 2017 | 70012 | 0.01 | Why? |
| Risk Factors | 2 | 2017 | 71621 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Heart | 1 | 2006 | 1791 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.01 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |